Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell ThesisSeeking Alpha • 02/04/26
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug OutlookThe Motley Fool • 02/03/26
Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026Market Watch • 02/03/26
Novo Nordisk stock tumbles 15% despite strong earnings: here's what spooked investorsInvezz • 02/03/26
Novo Nordisk Crashes After Projecting A 2026 Sales, Profit SlowdownInvestors Business Daily • 02/03/26
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes StudyZacks Investment Research • 02/03/26
Citi flags bigger tests ahead after Novo Nordisk diabetes trial successProactive Investors • 02/03/26
Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patientsReuters • 02/02/26
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trialGlobeNewsWire • 02/02/26